PAC Meeting April 2007
Minimal use in pediatric patients
Additional cases of cholelithiasis identified
Labeling reflects an increased risk of
gallstone formation with substantial weight
FDA recommends routine monitoring of
AEs for this drug in all populations.
AE reporting for nonprescription products
will be required in the near future.
Does the Advisory Committee concur?